Advertisement

Pharmaceutical Research

, 36:19 | Cite as

HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin

  • Sarita Rani
  • Avinash Gothwal
  • Pawan K. Pandey
  • Devendra S. Chauhan
  • Praveen K. Pachouri
  • Umesh D. Gupta
  • Umesh Gupta
Research Paper

Abstract

Purpose

Tuberculosis (TB) chemotherapy witnesses some major challenges such as poor water-solubility and bioavailability of drugs that frequently delay the treatment. In the present study, an attempt to enhance the aqueous solubility of rifampicin (RMP) was made via co-polymeric nanoparticles approach. HPMA (N-2-hydroxypropylmethacrylamide)-PLGA based polymeric nanoparticulate system were prepared and evaluated against Mycobacterium tuberculosis (MTB) for sustained release and bioavailability of RMP to achieve better delivery.

Methodology

HPMA-PLGA nanoparticles (HP-NPs) were prepared by modified nanoprecipitation technique, RMP was loaded in the prepared NPs. Characterization for particle size, zeta potential, and drug-loading capacity was performed. Release was studied using membrane dialysis method.

Results

The average particles size, zeta potential, polydispersity index of RMP loaded HPMA-PLGA-NPs (HPR-NPs) were 260.3 ± 2.21 nm, −6.63 ± 1.28 mV, and 0.303 ± 0.22, respectively. TEM images showed spherical shaped NPs with uniform distribution without any cluster formation. Entrapment efficiency and drug loading efficiency of HPR-NPs were found to be 76.25 ± 1.28%, and 26.19 ± 2.24%, respectively. Kinetic models of drug release including Higuchi and Korsmeyer-peppas demonstrated sustained release pattern. Interaction studies with human RBCs confirmed that RMP loaded HP-NPs are less toxic in this model than pure RMP with (p < 0.05).

Conclusions

The pathogen inhibition studies revealed that developed HPR-NPs were approximately four times more effective with (p < 0.05) than pure drug against sensitive Mycobacterium tuberculosis (MTB) stain. It may be concluded that HPR-NPs holds promising potential for increasing solubility and bioavailability of RMP.

Keywords

HPMA (N-2-hydroxypropylmethacrylamide) nanoparticles (NPs) PLGA rifampicin (RMP) solubility tuberculosis (TB) 

Abbreviations

ACN

Acetonitrile

ETB

Ethambutol

HPMA

N-2-hydroxypropylmethacrylamide co-polymer

HP-NPs

HPMA-PLGA nanoparticles

HPR-NPs

Rifampicin loaded HPMA-PLGA nanoparticles

INH

Isoniazid

MABA

Microplate Alamar Blue Assay

MTB

Mycobacterium tuberculosis

MIC

Minimum inhibitory concentration

NPs

Nanoparticles

PLGA

Poly-lactic-co-glycolic acid

PNPs

Polymeric Nanoparticles

PPB

Plasma protein binding

PYZ

Pyrazinamide

RMP

Rifampicin

STP

Streptomycin

TB

Tuberculosis

TEM

Transmission electron microscopy

WHO

World Health Organization

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

The authors acknowledge the financial support from the Rajasthan Department of Science and Technlogy, Jaipur India and Department of Science and Technology, New Delhi, India through DST Start up Research Grant (Young Scientists) to Dr. Umesh Gupta. Authors would also like to acknowledge Indian Council of Medical Research (ICMR) for providing facilities at JALMA, Agra, India. The authors declare no competing financial interest.

References

  1. 1.
    World Health Organization Treatment of tuberculosis: guidelines for national programmes Geneva: WHO Global Tuberculosis Report 2017.Google Scholar
  2. 2.
    Sosnik A, Carcaboso R, Glisoni M, Chiappetta MD. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2010;62:547–59.CrossRefPubMedGoogle Scholar
  3. 3.
    World Health Organization Communicable Diseases Cluster: Fixed-dose combination tablets for the treatment of tuberculosis 1999.Google Scholar
  4. 4.
    Mitchison DA. Role of individual drug in chemotherapy of tuberculosis. Int J Tuber Lung Dis. 2000;4:790–800.Google Scholar
  5. 5.
    Joshi JM. Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India. 2011;28:193–200.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuber Lung Dis. 2009;13:1320–30.Google Scholar
  7. 7.
    Ain QU, Sharma S, Khuller GK, Garg SK. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetic and therapeutic effects. J Antimicrob Chemother. 2003;51:931–8.CrossRefGoogle Scholar
  8. 8.
    Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (INH and RMP) encapsulated in liposomes. Int J Antimicrob Agents. 2002;20:301–4.Google Scholar
  9. 9.
    Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target. 2007;15:163–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Desjardins M, Griffiths G. Phagocytosis: latex leads the way. Curr Opin Cell Biol. 2003;15:498–503.CrossRefPubMedGoogle Scholar
  11. 11.
    Pandey R, Khuller GK. Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J Exp Biol. 2006;44:357–66.PubMedGoogle Scholar
  12. 12.
    Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother. 2004;53:635–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer–anticancer drug conjugates: design activity and mechanism of action. Eur J Pharm Biopharm. 2000;50:61–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans. 2007;35:56–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Rihova B, Ulbrich K, Kopecek J, Mancal P. Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol. 1983;28:217–27.CrossRefPubMedGoogle Scholar
  17. 17.
    Ulbrich K, Subr V, Strohalm J, Plocova D, Jelinkova M, Rihova B. Polymeric drugs based on conjugates of synthetic and natural macromolecules synthesis and physico-chemical characterization. J Control Release. 2000;64:63–79.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang D, Kopeckova JP, Minko T, Nanayakkara V, Kopecek J. Synthesis of starlike N-(2-hydroxypropyl) methacrylamide copolymers: potential drug carriers. Biomacromolecules. 2000;1:313–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Dvorak M, Kopeckova P, Kopecek J. High-molecular weight HPMA copolymer–adriamycin conjugates. J Control Release. 1999;60:321–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Chytil P, Etrych T, Kriz J, Subr V, Ulbrich K. N-(2-Hydroxypropyl) methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting synthesis by RAFT polymerisation and physicochemical characterization. Eur J Pharm Sci. 2010;41:473–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, et al. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30:1627–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Tomcin S, Kelsch A, Staff RH, Landfester K, Zentel R, Mailander V. HPMA-based block copolymers promote differential drug delivery kinetics for hydrophobic and amphiphilic molecules. Acta Biomater. 2015;35:12–22.CrossRefGoogle Scholar
  23. 23.
    Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004;57:251–26.CrossRefPubMedGoogle Scholar
  24. 24.
    Song H, Geng H, Ruan J, Wang K, Bao CN, Wang J, et al. Development of Polysorbate 80/phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res Lett. 2011;6:354.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of Ketoprofen. Pharmaz. 1997;52:149–51.Google Scholar
  26. 26.
    Franzblau SG, Witzig RS, Mclaughlin JC, Torres P, Madico G, Hernandez A, et al. Rapid low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar blue assay. J Clin Microbiol. 1998:362–6.Google Scholar
  27. 27.
    Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, Roos N, Madsen P, Koster G, Egge-Jacobsen W, Wilson S, Roberg-Larsen H, Khuller GK, Singh A, Nystrom B and Griffiths G. Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci. 2013;126:3034–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Kopecekj J, Copolymers KPHPMA. Origins early developments present and future. Adv Drug Deliv Rev. 2010;62:122–49.CrossRefGoogle Scholar
  29. 29.
    Khan I, Gothwal A, Sharma AK, Qayumb A, Singh SK, Gupta U. Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine. Int J Biol Macromol. 2016;92:1242–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Pelizza G, Nebuloni M, Ferrari P, Gallo GG. Polymorphism of rifampicin II. Farmaco. 1977;32:471–81.Google Scholar
  31. 31.
    Jindal KC, Chaudhary RS, Singla AK, Gangwal SS, Khanna S. Dissolution test methods for rifampicin-isoniazid fixed dose formulations. J. Pharm Biomed Anal. 1995;57:420–2.Google Scholar
  32. 32.
    Woo J, Cheung W, Chan R, Chan HS, Cheng A, Chan K. In vitro binding characterstics of isoniazid, rifampicin and pyrazinamide to whole plasma, albumin and α-1-acid glycoprotein. Clin Biochem. 1996;29:175–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Bergogne-Berezin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet. 2002;41:741–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration II studies in man. J Antimicrob Chemother. 1983;12:105–18.CrossRefPubMedGoogle Scholar
  35. 35.
    Costa P and Lobo JMS. Modeling and comparision of dissolution profiles. Eur J Pharm Sci 2001;13:123–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Nan A, Nanayakkara NP, Walker LA, Yardley V, Croft SL, Ghandehari H. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J Control Release. 2001;77:233–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy, School of Chemical Sciences and PharmacyCentral University of RajasthanAjmerIndia
  2. 2.ICMR-National JALMA Institute for Leprosy and Other Mycobacterial DiseasesAgraIndia

Personalised recommendations